Clarification on Biosimilar Activities

October 05,2012

Basel, 05 October 2012 – Following several reports and rumors in the past few days in relation to the Biosimilar activities of the joint venture of Lonza and Teva, Lonza wants to clarify the current situation on rituximab.  

Given the changes to the regulatory environment, Teva and Lonza (through their joint venture) are still evaluating the path forward for a Phase III trial based on the latest changes in the regulatory environment. Further updates will be provided once new information becomes available.

Browse All News